Global healthcare contract development and manufacturing organization (CDMO) market was valued at $250.8 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). The global healthcare contract development and manufacturing organization (CDMO) market is evolving as pharmaceutical and biotechnology companies increasingly externalize development and manufacturing activities to improve efficiency and focus on core research. Growing product portfolios, shorter development timelines, and rising regulatory expectations are encouraging sponsors to collaborate with specialized partners that offer integrated services across the product lifecycle. CDMOs are responding by expanding end-to-end capabilities, from early formulation and analytical development to commercial-scale manufacturing. Technology adoption, including automation and digital quality systems, is becoming more prevalent to enhance consistency and compliance. At the same time, clients are prioritizing long-term partnerships that provide flexibility, capacity reliability, and technical depth. These dynamics reflect a market shaped by operational complexity, compliance rigor, and the need for scalable manufacturing solutions.
Browse the full report description of “Healthcare Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/healthcare-cdmo-market
Healthcare CDMO Market Embraces Growing Outsourcing Trend for Biologics Production
The Healthcare CDMO market is witnessing a strong transformation as pharmaceutical and biotech companies increasingly rely on external partners for complex biologic production. Facilities are shifting operations to specialized CDMOs to enhance efficiency and focus on innovation. This trend reflects growing confidence in outsourcing and collaboration with manufacturing partners. The industry is evolving to meet rising demand for biologics while optimizing internal resources. Investments in external capabilities are reshaping how biologics are developed and produced globally.
Global Healthcare CDMO Market: Presence of Established and Diversified Service Providers
The key players in the Healthcare CDMO market are Thermo Fisher Scientific Inc., Lonza Group AG, Catalent, Inc., Samsung Biologics Co., Ltd., and WuXi Biologics Co., Ltd., among others. These organizations operate across multiple stages of the pharmaceutical and biotechnology value chain, offering a broad range of development and manufacturing services. Investments are being directed toward capacity expansion, advanced manufacturing technologies, and digital quality systems to improve efficiency and regulatory compliance. The market is characterized by long-term collaborations with pharmaceutical and biotech companies seeking reliability, scalability, and technical expertise. Competitive differentiation increasingly depends on service breadth, global manufacturing footprints, and the ability to manage complex regulatory environments.
Market Coverage
Key questions addressed by the report.
Global Healthcare CDMO Market Report Segment
By Services
Global Healthcare CDMO Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/healthcare-cdmo-market